Last reviewed · How we verify
Cefadrox (CEFADROXIL)
Cefadroxil is a small molecule antibiotic in the cefadroxil class, targeting the solute carrier family 15 member 1. It was originally developed and is currently owned by Warner Chilcott. FDA approved in 1978, cefadroxil is used to treat various bacterial infections, including urinary tract infections, skin infections, and streptococcal infections. The drug has a high bioavailability of 95% and a short half-life of 1.1 hours. Cefadroxil is off-patent, with 18 generic manufacturers available.
At a glance
| Generic name | CEFADROXIL |
|---|---|
| Sponsor | Warner Chilcott |
| Drug class | cefadroxil |
| Target | Solute carrier family 15 member 1 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 1978 |
Approved indications
- Escherichia coli urinary tract infection
- Infection due to Staphylococcus aureus
- Infection of skin AND/OR subcutaneous tissue
- Klebsiella cystitis
- Proteus urinary tract infection
- Streptococcal tonsillitis
- Streptococcus pyogenes infection
- Tonsillitis
- Urinary tract infectious disease
Common side effects
- Toxic epidermal necrolysis
- Renal dysfunction
- Toxic nephropathy
- Aplastic anemia
- Hemolytic anemia
- Hemorrhage
- Prolonged prothrombin time
- Positive Coombs test
- Increased BUN
- Increased creatinine
- Elevated alkaline phosphatase
- Elevated aspartate aminotransferase (AST)
Key clinical trials
- Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing (PHASE2)
- A Platform Trial for Gram Negative Bloodstream Infections (NA)
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Antibiotic Prophylaxis in High-Risk Arthroplasty Patients (PHASE4)
- BALANCE+ Vanguard Phase (NA)
- Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA (PHASE3)
- Cefadroxil 500 mg Capsules in Normal Healthy Non-Smoking Male and Female Subjects. (PHASE1)
- Cefadroxil 500 mg Capsules Under Fasting Conditions (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cefadrox CI brief — competitive landscape report
- Cefadrox updates RSS · CI watch RSS